Phaseline

Companies › Shionogi

Shionogi: clinical trials, targets and expected readouts

10 active drug programs in 30 registered trials: 11 Phase 1, 11 Phase 2, 5 Phase 4, 3 Phase 3; Respiratory, Infectious disease, Metabolic and endocrine, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Secutrelvir
SARS-CoV-2 3CL protease inhibitor
3CLPhase 3COVID-19; SARS-CoV-2Jul 2027
S-337395
RSV antiviral agent
–Phase 2Respiratory Syncytial Virus InfectionsDec 2026
Acetazolamide
Carbonic anhydrase I inhibitor; Carbonic anhydrase II inhibitor; Carbonic anhydrase XII inhibitor
CA1, CA2, CA12, CA4Phase 2Sleep Apnea; Hypobaric Hypoxia; High Altitude Effects; Post Operative Pain …Dec 2026
SASS-001–Phase 2Sleep ApneaDec 2026
Sivopixant
CRF1 receptor antagonist
CRHR1Phase 2Sleep ApneaDec 2026
S-606001
Unclear - mechanism not specified
–Phase 2Pompe DiseaseAug 2027
Zatolmilast (BPN14770)
Phosphodiesterase 4D inhibitor
PDE4DPhase 2Jordan's SyndromeDec 2027
S-531011–Phase 1Solid TumorsMay 2028
Naldemedine
Mu opioid receptor antagonist
OPRM1Phase 1Opioid-Induced Constipation (OIC)Jun 2028
S-892216-LAI–Phase 1Healthy ParticipantsJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05300477AcetazolamidePhase 4Hypobaric HypoxiaOtherSep 2023
NCT07118462AcetazolamidePhase 4High Altitude EffectsOtherDec 2025
NCT05293600AcetazolamidePhase 1Obstructive Sleep ApneaRespiratoryOct 2026
NCT05804084AcetazolamidePhase 2Obstructive Sleep ApneaRespiratoryOct 2026
NCT07101250AcetazolamidePhase 4Post Operative PainOtherDec 2026
NCT06981234AcetazolamidePhase 2Type 1 DiabetesMetabolic and endocrineDec 2026
NCT03011671AcetazolamidePhase 1Malignant Glioma of BrainOncologyDec 2026
NCT07214571S-337395Phase 2Respiratory Syncytial Virus InfectionsInfectious diseaseDec 2026
NCT06776432SivopixantPhase 2Sleep ApneaRespiratoryDec 2026
NCT06776432AcetazolamidePhase 2Sleep ApneaRespiratoryDec 2026
NCT04118387AcetazolamidePhase 4Sleep Disordered BreathingRespiratoryDec 2026
NCT05589753AcetazolamidePhase 1Sleep ApneaPsychiatryDec 2026
NCT06776432SASS-001Phase 2Sleep ApneaRespiratoryDec 2026
NCT07372040AcetazolamidePhase 2Acute Decompensated Heart FailureCardiovascularFeb 2027
NCT05470283AcetazolamidePhase 1TumorOncologyApr 2027
NCT03467360AcetazolamidePhase 1Small Cell Lung CancerOncologyApr 2027
NCT02703220AcetazolamidePhase 4Sleep ApneaRespiratoryJul 2027
NCT07746544SecutrelvirPhase 3COVID-19Infectious diseaseJul 2027
NCT07123155S-606001Phase 2Pompe DiseaseMetabolic and endocrineAug 2027
NCT06091085AcetazolamidePhase 1OSANeurologyDec 2027
NCT04887792AcetazolamidePhase 1SchizophreniaPsychiatryDec 2027
NCT06717438Zatolmilast (BPN14770)Phase 2Jordan's SyndromePsychiatryDec 2027
NCT06521476AcetazolamidePhase 2Central Sleep Apnea Comorbid With Opioid UsePsychiatryFeb 2028
NCT06166654AcetazolamidePhase 3Acute Heart FailureCardiovascularMar 2028
NCT05101070S-531011Phase 1Solid TumorsOncologyMay 2028
NCT05588323NaldemedinePhase 1Opioid-Induced Constipation (OIC)GastroenterologyJun 2028
NCT07743580SecutrelvirPhase 3SARS-CoV-2Infectious diseaseJun 2028
NCT07093580S-892216-LAIPhase 1Healthy ParticipantsInfectious diseaseJun 2028
NCT05953610AcetazolamidePhase 2Obstructive Sleep ApneaRespiratoryAug 2028
NCT00262470AcetazolamidePhase 1TachycardiaOtherDec 2029

Targets

OPRM1 (1) CRHR1 (1) CA1 (1) CA2 (1) CA12 (1) CA4 (1) PDE4D (1) 3CL (1)

Companies with the same targets

Inventage Lab. Upsher-Smith Laboratories Trevi Therapeutics Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Boulder Care Adneuris Therapeutics Ensysce Biosciences

Companies built like this

Valenta Pharm JSC Chiesi Farmaceutici Sunshine Lake Pharma Fujian Shengdi Pharmaceutical Shenzhen Salubris Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.